Clinical trials: Advanced Digestive System Tumor
Liver Cancer, Hepatocellular Carcinoma
Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma
The present protocol (STRAT-aHCC trial) aims to prospectively evaluate the tolerability, quality of life and efficacy of an alternative regimen of regorafenib in patients with advanced hepatocellular carcinoma (HCC) after…
- Trial name
- STRAT-aHCC (NCT05622136)
- Testing
- Regorafenib Oral Product
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Pancreatic Neoplasms, Melanoma
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
- Conditions
- Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms
- Trial name
- NCT00844064
- Testing
- AP 12009
- Where
- 10 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Isarna Therapeutics GmbH
Colorectal Cancer
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00541112
- Testing
- cetuximab, capecitabine, fluorouracil
- Where
- 10 sites in France
- Volunteers
- 19 people
- Sponsor
- UNICANCER
Carcinoma, Hepatocellular
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
This is a Phase II study of single agent ABC294640. Patients with advanced hepatocellular carcinoma (HCC) who have experienced tumor progression or unacceptable toxicity on single agent sorafenib will receive ABC294640 500 mg by…
- Trial name
- NCT02939807
- Testing
- ABC294640
- Where
- United States
- Sponsor
- Medical University of South Carolina
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
This phase II trial is studying how well giving cediranib maleate together with combination chemotherapy works in treating patients with advanced biliary cancers.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01229111
- Testing
- cediranib maleate, oxaliplatin, leucovorin calcium
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Lymph Node Metastasis
Staging LaParoscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer
Staging LaParscopy to Assess Lymph NOde InvoLvement in Advanced GAstric Cancer (POLA) study aims to investigate the safety and feasibility of ICG-guided SN retrieval in GC patients undergoing multimodal treatment.
- Trial name
- POLA (NCT05720598)
- Testing
- Sentinel Node Assessment, Staging laparoscopy, Gastroscopy with indocyanine green (ICG) injection
- Where
- Poland
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Medical University of Lublin
Breast Cancer, Colorectal Cancer
SU006668 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer
- Trial name
- NCT00024063
- Testing
- orantinib
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is…
- Trial name
- NCT07235293
- Testing
- DSP107 + Atezolizumab, Fruquintinib
- Where
- 18 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Kahr Bio Australia Pty Ltd
Gastric Cancer
Docetaxel and Epirubicin as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma of the Stomach
RATIONALE: Drugs used in chemotherapy, such as docetaxel and epirubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00075465
- Testing
- docetaxel, epirubicin hydrochloride
- Where
- 23 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastric Cancer
POF Versus FOLFOX Plus IP Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.
- Trial name
- NCT04155671
- Testing
- POF, FOLFOX plus PAC(ip)
- Volunteers
- 260 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer
New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX
To evaluate the efficacy and safety of carelizumab combined with XELOX regimen in neoadjuvant treatment of locally advanced resectable gastric cancer
- Trial name
- NCT05715632
- Testing
- Carrelizumab combined with XELOX
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tang-Du Hospital
Gastric Cancer
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00683787
- Testing
- docetaxel, vandetanib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Neuroendocrine Tumor
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
A Phase II Randomized,Controlled,Open Label,Multicentre Study to evaluate the efficacy and safety of Tegafur combined with Temozolomide versus Tegafur combined with Temozolomide and Thalidomide in subjects with Advanced…
- Trial name
- NCT03204019
- Testing
- Tegafur and Temozolomide, Tegafur and Temozolomide combined with Thalidomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese Academy of Medical Sciences
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
This study is designed to assess the safety and preliminary activity of SBT6050 in combination with trastuzumab deruxtecan (Part 1) or tucatinib plus trastuzumab +/- capecitabine (Part 2).
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
- Trial name
- NCT05091528
- Testing
- SBT6050, trastuzumab deruxtecan, tucatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Silverback Therapeutics
Carcinoma, Hepatocellular
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
This study is to evaluate the efficacy and safety of Sorafenib in combination with Gemcitabine in patients with advanced/unresectable HCC.
- Trial name
- NCT00703365
- Testing
- Sorafenib and Gemcitabine
- Where
- 3 sites in Thailand
- Volunteers
- 45 people
- Sponsor
- Mahidol University
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of…
- Trial name
- NCT03713593
- Testing
- lenvatinib, pembrolizumab
- Where
- 172 sites in United States, Australia and 19 more
- Volunteers
- 794 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Cancer
Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer
This prospective, multicenter clinical study evaluates the efficacy and safety of NALIRIFOX in combination with Stereotactic Body Radiation Therapy (SBRT) for patients with locally advanced unresectable pancreatic cancer.
- Trial name
- RAD-NALIRIFOX (NCT07173387)
- Testing
- NALIRIFOX (liposomal irinotecan-based chemotherapy)., Stereotactic Body Radiation Therapy (SBRT).
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
In this study, participants with locally advanced rectal cancer patients will be treated according to MMR/MSI status. There will be two cohorts in this study: Cohort A and Cohort B.
- Trial name
- NCT04304209
- Testing
- Oxaliplatin, Capecitabine, Sintilimab
- Where
- China
- Volunteers
- 195 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer with Hepatic Metastases
TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc…
- Trial name
- NCT06834399
- Testing
- KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Primary Malignant Neoplasm of Lung, Primary Malignant Neoplasm of Gastrointestinal Tract
Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
To assess the feasibility of a creative writing intervention in an advanced cancer population. Given it is a relatively simple intervention delivered by a non-clinician, the investigators are interested in better understanding…
- Trial name
- NCT02575898
- Testing
- First Session, Second Session, Third through Sixth Sessions
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.